CTOs on the Move

Abnova Corporation

www.abnova.com

 
Abnova Corporation is a Walnut, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.abnova.com
  • 20153 Paseo Del Prado
    Walnut, CA USA 91789
  • Phone: 909.839.7620

Executives

Name Title Contact Details

Similar Companies

Evolution Medical Communications

Evolution Medical Communications, LLC is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vector Laboratories Inc

Vector Laboratories Inc is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SenesTech

Left unchecked, two base rats, a male and a female, can result in 15,000 descendants in about 12 months. It`s easy to see how quickly this can lead to infestations and even population rebounds if just two rats are left behind after a knockdown program. That`s where we come in. We`re SenesTech, the rat fertility experts and the makers of ContraPest®, the first and only EPA-registered rat fertility restrictor impacting both male and female rats. We make it possible to target both ends of the lifecycle—birth and death—by adding fertility control to your integrated pest management (IPM) solution. Controlling the birth rate with ContraPest will magnify the success of your existing IPM protocols. ContraPest is the one-of-a-kind, innovative technology that targets the reproductive capabilities of both male and female Norway and roof rats. Sweet and fatty, it`s highly palatable like a “milkshake” rats can`t get enough of. By using ContraPest, you can reduce the rat population and keep it down because ContraPest works!

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zucara Therapeutics

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.